Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Medicare evaluating Aduhelm coverage while Democrats ask Biogen for documents 

While CMS is mulling potential coverage of the Alzheimer’s drug, Democrats are seeking information on the approval process of the therapy. 

By Brian Buntz | July 13, 2021

BiogenAs Medicare officials review evidence about Biogen’s (NSDQ:BIIB) Aduhelm (aducanumab) to determine if and how it will cover the drug, two high-level House Democrats are asking Biogen about its dealings with FDA. 

Yesterday, Carolyn Maloney (D-N.Y.) and Frank Pallone, Jr. (D-N.J.) sent a letter to Biogen CEO Michel Vounatsos asking for details about the company’s communications with FDA staff before it filed a Biologics License Application for aducanumab. Maloney chairs the House Committee on Oversight and Reform, while Pallone chairs the House Committee on Energy and Commerce.

The House isn’t alone in its push for such information regarding the drug, which could cost patients $56,000 annually in out-of-pocket expense. Acting FDA Commissioner Dr. Janet Woodcock recently asked the Office of Inspector General to launch an independent review of the agency’s dealings with Biogen during the Aduhelm approval process. 

Public Citizen recently filed a letter to Christi Grimm, principal deputy inspector general at the Office of the Inspector General (OIG), asking that the Office of Inspector General investigate Dr. Woodcock as part of its probe.

Analysts expect Aduhelm to be an eventual blockbuster drug, but the company does face risks related to Aduhelm pushback and potential U.S. drug pricing reform. Roughly 60% of its sales are in the U.S., but such concerns are not material to the firm’s valuation, according to an analysis from Morningstar healthcare strategist Karen Andersen. 

CMS anticipates that it will make a coverage decision on Aduhelm in the next six months. Once it reaches a conclusion, it will allow the public to submit comments for 30 days. 

The agency’s decision will also likely serve as a model for other potential drugs that target amyloid, a protein found in the brains of Alzheimer’s patients. 


Filed Under: Uncategorized
Tagged With: Aducanumab, Aduhelm, Biogen, Carolyn Maloney, CMS, Frank Pallone, Medicare
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Amylyx
Amylyx notches first global approval for oral ALS therapy Albrioza
Novavax
FDA advisory panel backs Novavax COVID-19
Sage and Biogen
Zuranolone could offer rapid relief from postpartum depression 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50